In the last twelve months, Genmab A/S generated $4.4 billion in revenue and $201.3 million in net income.
BofA Merrill Lynch, Morgan Stanley and Jefferies acted as the underwriters for the IPO and Guggenheim Securities and RBC Capital Markets were co-managers.
Genmab A/S provided the following description of their company for its IPO: “(Note (a public offering): Currently, our ordinary shares are listed on Nasdaq Copenhagen A/S, or Nasdaq Copenhagen, under the symbol “GEN” and our ADSs are traded on the over-the-counter market in the United States under the symbol “GMXAY.”) We are an international biotechnology company specializing in antibody therapeutics for the treatment of cancer and other diseases. Our core purpose is to improve the lives of patients by creating and developing innovative antibody products. Our vision is to transform cancer treatment by launching our own proprietary product by 2025 and advancing our pipeline of differentiated and well-tolerated antibodies. We are building and expanding our late-stage development and commercial capabilities to allow us to bring our proprietary products to market in the future. Today, we have a well-diversified portfolio of products, product candidates and technologies. Our portfolio includes two marketed partnered products, daratumumab, marketed as DARZALEX for the treatment of certain indications of multiple myeloma, or MM, and ofatumumab, marketed as Arzerra for the treatment of certain indications of chronic lymphocytic leukemia, or CLL, in addition to a broad pipeline of differentiated product candidates. “.
Genmab A/S was founded in 1998 and has 419 employees. The company is located at Kalvebod Brygge 43, 1560 Copenhagen V, Denmark and can be reached via phone at +45 70 20 27 28. or on the web at http://www.genmab.com.
Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.